drugset / Trial / NCT00151762

Long-Term Study of Safety and Efficacy of WelChol® as an Additional Therapy in Patients With Type 2 Diabetes

NCT00151762

Phase 3 Completed 780 enrolled Daiichi Sankyo
Non-randomizedOpen-labelTreatment

Summary

This extension study is designed to evaluate the long-term safety and tolerability of colesevelam hydrochloride (WelChol®) in patients with type 2 diabetes.

Timeline

Start
2004-12
Primary completion
2007-07
Completion
2007-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Colesevelam Other / unclassified